Cynapsus Therapeutics Enrolls First Patient in Pivotal Phase 3 Safety Study of APL-130277 for the Treatment of OFF Episodes in Patients With Parkinson’s Disease

TORONTO, Sept. 2, 2015 (GLOBE NEWSWIRE) — Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH) (the “Company”) today announced enrollment of the first patient in the CTH-301 clinical trial, a pivotal Phase 3 study to examine the safety and tolerability of APL-130277 for the acute treatment of OFF episodes in patients with Parkinson’s disease (PD). CTH-300, a pivotal Phase 3 efficacy study, is also ongoing with data expected from both trials in 2016. – See more at: http://globenewswire.com/news-release/2015/09/02/765695/10148122/en/Cynapsus-Therapeutics-Enrolls-First-Patient-in-Pivotal-Phase-3-Safety-Study-of-APL-130277-for-the-Treatment-of-OFF-Episodes-in-Patients-With-Parkinson-s-Disease.html#sthash.DBIbRcUH.dpuf